Once Daily Valacyclovir for Reducing Viral Shedding in Subjects Newly Diagnosed with Genital Herpes
Joint Authors
Brennan, Clare A.
Martens, Mark G.
Dix, Lynn P.
Leone, Peter A.
Fife, Kenneth H.
Source
Infectious Diseases in Obstetrics and Gynecology
Issue
Vol. 2009, Issue 2009 (31 Dec. 2009), pp.1-7, 7 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2009-08-10
Country of Publication
Egypt
No. of Pages
7
Main Subjects
Abstract EN
Objective.
Genital herpes (GH) recurrences and viral shedding are more frequent in the first year after initial HSV-2 infection.
The objective of this study was to provide the first evaluation of valacyclovir 1 g once daily compared to placebo in reducing viral shedding in subjects newly diagnosed with GH.
Methods.
70 subjects were randomized to receive valacyclovir 1 g daily or placebo in a crossover design for 60 days with a 7-day washout period.
A daily swab of the genital/anal-rectal area was self-collected for HSV-2 detection by PCR.
Subjects attended the clinic for routine study visits and GH recurrence visits.
Treatment differences were assessed using a nonparametric crossover analysis.
Results.
52 subjects had at least one PCR measurement in both treatment periods and comprised the primary efficacy population.
Valacyclovir significantly reduced HSV-2 shedding during all days compared to placebo (mean 2.9% versus 13.5% of all days (P<.01), a 78% reduction).
Valacyclovir significantly reduced subclinical HSV-2 shedding during all days compared to placebo (mean 2.4% versus 11.0% of all days (P<.01), a 78% reduction).
However, 79% of subjects had no GH recurrences while receiving valacyclovir compared to 52% of subjects receiving placebo (P<.01).
Conclusion.
In this study, the frequency of total and subclinical HSV-2 shedding was greater than reported in earlier studies involving subjects with a history of symptomatic genital recurrences.
Our study is the first to demonstrate a significant reduction in viral shedding with valacyclovir 1 g daily compared to placebo in a population of subjects newly diagnosed with HSV-2 infection.
American Psychological Association (APA)
Martens, Mark G.& Fife, Kenneth H.& Leone, Peter A.& Dix, Lynn P.& Brennan, Clare A.. 2009. Once Daily Valacyclovir for Reducing Viral Shedding in Subjects Newly Diagnosed with Genital Herpes. Infectious Diseases in Obstetrics and Gynecology،Vol. 2009, no. 2009, pp.1-7.
https://search.emarefa.net/detail/BIM-446767
Modern Language Association (MLA)
Martens, Mark G.…[et al.]. Once Daily Valacyclovir for Reducing Viral Shedding in Subjects Newly Diagnosed with Genital Herpes. Infectious Diseases in Obstetrics and Gynecology No. 2009 (2009), pp.1-7.
https://search.emarefa.net/detail/BIM-446767
American Medical Association (AMA)
Martens, Mark G.& Fife, Kenneth H.& Leone, Peter A.& Dix, Lynn P.& Brennan, Clare A.. Once Daily Valacyclovir for Reducing Viral Shedding in Subjects Newly Diagnosed with Genital Herpes. Infectious Diseases in Obstetrics and Gynecology. 2009. Vol. 2009, no. 2009, pp.1-7.
https://search.emarefa.net/detail/BIM-446767
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-446767